Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.5719
+0.0230 (4.19%)
At close: Dec 24, 2025, 1:00 PM EST
0.5688
-0.0031 (-0.54%)
After-hours: Dec 24, 2025, 4:59 PM EST
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.40M in the quarter ending September 30, 2025, a decrease of -4.05%. This brings the company's revenue in the last twelve months to $5.26M, down -8.16% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.26M
Revenue Growth
-8.16%
P/S Ratio
4.93
Revenue / Employee
$250,381
Employees
21
Market Cap
78.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
| Dec 31, 2018 | 2.98M | -739.00K | -19.85% |
| Dec 31, 2017 | 3.72M | -3.00M | -44.65% |
| Dec 31, 2016 | 6.72M | -97.00K | -1.42% |
| Dec 31, 2015 | 6.82M | 4.18M | 157.88% |
| Dec 31, 2014 | 2.65M | -2.43M | -47.87% |
| Dec 31, 2013 | 5.07M | -718.00K | -12.40% |
| Dec 31, 2012 | 5.79M | 3.78M | 187.73% |
| Dec 31, 2011 | 2.01M | -360.00K | -15.17% |
| Dec 31, 2010 | 2.37M | -6.52M | -73.32% |
| Dec 31, 2009 | 8.89M | 6.57M | 282.49% |
| Dec 31, 2008 | 2.33M | -2.93M | -55.77% |
| Dec 31, 2007 | 5.26M | -1.22M | -18.82% |
| Dec 31, 2006 | 6.48M | 6.11M | 1,645.55% |
| Dec 31, 2005 | 371.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PSTV News
- 13 days ago - Plus Therapeutics Expands CNSide Assay Platform to State of California - GlobeNewsWire
- 15 days ago - Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - GlobeNewsWire
- 20 days ago - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - GlobeNewsWire
- 23 days ago - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 - GlobeNewsWire